Trial · NCT07432516
Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial
NCT07432516, Not applicable, Not yet recruiting, Yonsei University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial. Trials, record NCT07432516. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07432516
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial
- NCT number
- NCT07432516
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 4,400 participants, estimated
- Lead sponsor
- Yonsei University
- Conditions
- Coronary Artery Disease
- Interventions
Discontinuation strategy + Combination lipid-lowering therapy, Switching strategy + Combination lipid-lowering therapy, Discontinuation strategy + High-intensity statin therapy, Switching strategy + High-intensity statin therapy
- First posted
- 2026-02-25
- Last updated
- 2026-02-25
Source ClinicalTrials.gov
Registered outcomes39
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major or Clinically-Relevant Non-Major Bleeding (OPACT-P) | Within 1 year after enrollment | Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding |
| Primary | Major Adverse Cardiac Events (OPACT-L) | Within 3 years after enrollment | A composite of all-cause death, spontaneous MI, stroke, coronary or peripheral revascularization, and hospitalization for cardiovascular events |
| Secondary | Key Secondray Outcomes for the OPACT-P trial | Withtin 1 and 3 years after enrollement | AA. MACCE (composite of all-cause death, spontaneous MI, stent thrombosis, stroke, or target-vessel revascularization) B. NACE: Major or clinically relevant non-major bleeding (BARC type 2, 3, 5) and MACCE C. BARC type 2 bleeding D. BARC type 3 bleeding E. BARC type 5 bleeding |
| Secondary | All-cause death (OPACT-P trial) | Withtin 1 and 3 years after enrollement | Number of participants who experienced all-cause death during the study period |
| Secondary | Cardiovascular death (OPACT-P trial) | Withtin 1 and 3 years after enrollement | Number of participants who experienced cardiovascular death during the study period |
| Secondary | Spontaneous MI (OPACT-P trial) | Withtin 1 and 3 years after enrollement | Number of participants who experienced spontaneous myocardial infarction during the study period |
| Secondary | Stroke (OPACT-P trial) | Withtin 3 years after enrollement | Number of participants who experienced stroke during the study period |
| Secondary | Target-vessel revascularization (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who underwent target-vessel revascularization during the study period |
| Secondary | Target-lesion revascularization (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who underwent target-lesion revascularization during the study period |
| Secondary | Definite or probable stent thrombosis (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who experienced definite or probable stent thrombosis during the study period |
1 to 10 of 39Source ClinicalTrials.gov
See all 39 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07432516
GET https://conductscience.org/api/trials/v1/NCT07432516/registered?page=2